Enrique M. Ocio, MD, PhD, of Marqués de Valdecilla University Hospital, Santander, Spain, presents updates from a Phase Ib study of isatuximab, bortezomib, cyclophosphamide and dexamethasone (VCd) or lenalidomide and dexamethasone (VRd) in transplant-ineligible newly diagnosed multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
